Brokers Set Expectations for Gossamer Bio FY2024 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Gossamer Bio in a report issued on Monday, November 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.18) per share for the year, up from their previous forecast of ($0.21). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Separately, Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $0.82 on Wednesday. The company’s fifty day simple moving average is $0.94 and its 200-day simple moving average is $0.86. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.60. The company has a market cap of $184.81 million, a PE ratio of -2.55 and a beta of 1.96.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $4.52 million.

Institutional Trading of Gossamer Bio

Several large investors have recently modified their holdings of GOSS. SG Americas Securities LLC purchased a new position in Gossamer Bio in the first quarter valued at about $34,000. US Bancorp DE purchased a new position in shares of Gossamer Bio during the 3rd quarter valued at approximately $39,000. Choreo LLC acquired a new stake in shares of Gossamer Bio during the second quarter worth approximately $46,000. GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio in the third quarter worth $67,000. Finally, Algert Global LLC acquired a new stake in Gossamer Bio in the second quarter valued at $75,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.